Immune checkpoint inhibitor-induced diabetes mellitus in metastatic NSCLC: a case report with extended follow-up and management considerations - Top-Institutions - MDSpire

Immune checkpoint inhibitor-induced diabetes mellitus in metastatic NSCLC: a case report with extended follow-up and management considerations

  • By

  • Daniele Nova

  • Gabriele Giuseppe Pagliari

  • Sara Mambrito

  • Diego Luigi Cortinovis

  • Stefania Canova

  • July 17, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Oncology

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

  • #4

    Winship Cancer Institute
    Winship Cancer Institute

    Atlanta, GA

    Key Differentiators

    • Oncology

  • #5

    Stephenson Cancer Center, University of Oklahoma
    Stephenson Cancer Center, University of Oklahoma

    Oklahoma City, OK

    Key Differentiators

    • Oncology

Original Source(s)

Immune checkpoint inhibitor-induced diabetes mellitus in metastatic NSCLC: a case report with extended follow-up and management considerations

  • by Daniele Nova, Gabriele Giuseppe Pagliari, Sara Mambrito, Diego Luigi Cortinovis, Stefania Canova

  • July 17, 2026

Related Content

Transformation from lung adenocarcinoma to pulmonary giant cell carcinoma following targeted therapy: a case report

Transplants extended survival for patients whose stage 4 lung cancer hadn’t spread, study says

Single-port robotic segmentectomy using the da Vinci SP system for non-small cell lung cancer